Tag Archives: comparative advertising claims

What Can Advertisers Learn from This Season’s Hot Topics?



From pharma and supplements, to pet products and AI, the same rule applies: advertisers need evidence that matches the claims. 

In the Season 6 finale of Ad Watchers, attorneys from the National Advertising Division (NAD) revisit some of the season’s hottest advertising topics and examine a new round of cases involving pharmaceutical products, GLP-1 weight loss programs, supplements, contact lenses, pet products, and AI-enabled technology.

The episode highlights six recurring principles:

  • Tailor claims to the evidence. Don’t make broader claims than your data supports. 
  • Substantiate health claims with reliable science. Health and wellness claims require appropriate scientific support. 
  • Context matters. Even promotional language can become an objective, measurable claim requiring evidence. 
  • Truthful claims can still mislead. NAD looks at the overall consumer takeaway, not just whether individual words are technically accurate. 
  • AI claims need AI-specific proof. Evidence must support what the technology itself can actually do, not just broader outcomes associated with its use.

The season finale offers advertisers practical examples of what is—and is not—working when NAD evaluates advertising claims across rapidly evolving industries.

Related Resources:

Chapters

00:00 – Welcome to the Ad Watchers Season 6 Finale
Introduces the final episode of the season and the National Advertising Division’s role in reviewing advertising claims and applying advertising law.

01:23 – The Advertising Trends NAD Is Continuing to Watch
Revisits major Season 6 categories, including pharmaceuticals, infant products, pet care, financial services, and influencer advertising, and introduces new cases in several of those areas.

01:54 – Dupixent Eczema Advertising Claims and Disclosures
Examines physician- and consumer-directed advertising for Dupixent, including claims around eczema control, clearer skin, inflammation, long-lasting results, itch relief, visual demonstrations, and disclosure requirements.

06:10 – GLP-1 Microdosing Claims: Puffery or Objective Advertising?
Reviews the challenge involving Noom’s GLP-1 microdosing program and the phrase “a smaller dose, a smarter start,” including why connecting “smarter” to a measurable dosage benefit transformed the message into an objective claim requiring substantiation.